Core Viewpoint - The article discusses the implementation of the commercial insurance drug directory (商保目录) in China, highlighting its significance for innovative drugs and the challenges faced in its execution [2][3][15]. Group 1: Overview of the Commercial Insurance Drug Directory - The commercial insurance drug directory includes 19 drugs, including CAR-T therapies and Alzheimer's medications, aimed at addressing the gap between basic medical insurance and patient affordability [2][3]. - As of January 20, 2026, 14 drugs from the directory have been sold in 223 designated medical institutions, primarily in major cities [5][6]. - The directory's implementation is seen as a milestone for the development of innovative drugs and commercial insurance in China, although many people have yet to feel its impact [2][3]. Group 2: Challenges in Implementation - The main challenge for hospitals is the process of getting drugs from the directory into their facilities, which involves multiple evaluations and approvals [5][6]. - Hospitals are cautious about introducing new drugs due to cost control pressures and various performance indicators that must be met [7][12]. - The "three exclusions" policy aims to alleviate concerns about the financial impact of new drugs on hospitals, but other factors still influence the decision to adopt these drugs [7][12]. Group 3: Discount and Pricing Issues - The commercial insurance directory allows for negotiated discounts on drug prices, which are not directly passed on to patients at the point of sale [9][10]. - There is confusion among stakeholders regarding how these discounts should be allocated, leading to potential disputes in implementation [10][11]. - The lack of clear guidelines on discount distribution complicates the relationship between insurance companies, drug manufacturers, and healthcare providers [10][11]. Group 4: Insurance Companies' Perspectives - Insurance companies are cautious about incorporating drugs from the directory into their products, often requiring detailed information on pricing and risk before making decisions [13][14]. - There is a lack of new insurance products specifically designed for the commercial insurance directory, with most companies opting to upgrade existing products [13][14]. - The directory's introduction is viewed positively by some pharmaceutical companies, as it represents government endorsement of their products, although challenges remain in achieving widespread adoption [15][16].